Dermata Therapeutics (NASDAQ:DRMA) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Dermata Therapeutics (NASDAQ:DRMA) issued its quarterly earnings data on Thursday. The company reported ($1.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.02, FiscalAI reports.

Dermata Therapeutics Price Performance

Shares of DRMA stock opened at $1.37 on Friday. Dermata Therapeutics has a one year low of $1.11 and a one year high of $23.70. The company’s fifty day moving average price is $1.63 and its 200-day moving average price is $2.85. The company has a market capitalization of $3.89 million, a price-to-earnings ratio of -0.18 and a beta of 0.60.

Institutional Investors Weigh In On Dermata Therapeutics

A hedge fund recently bought a new stake in Dermata Therapeutics stock. Clear Street Group Inc. acquired a new stake in Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned approximately 0.60% of Dermata Therapeutics as of its most recent SEC filing. 8.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on DRMA shares. Weiss Ratings reiterated a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday, December 29th. Wall Street Zen cut Dermata Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Dermata Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.